Merck & Co., Inc.(MRK)
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest News & Analysis
Merck's Cardiovascular Gambit: Enlicitide Oral PCSK9 Opens Third Pillar of Diversification
Enlicitide Phase 3 validates Merck's oral PCSK9 entry into $47B cardiovascular market, challenging Amgen and Regeneron duopoly.
Merck Navigates Legal and Regulatory Challenges
Merck faces legal, regulatory, and market challenges today amid securities lawsuits and delayed vaccine trials, as our analysis reveals.
Merck Faces Investor Lawsuits Amid Gardasil Sales Concerns and Vaccine Case Delay
A series of class action lawsuits and a delayed vaccine trial are challenging Merck, forcing scrutiny of Gardasil sales and future growth.
Merck (MRK) Under Investigation: Impact on Investors
Merck (MRK) faces securities fraud investigations amid Keytruda's success and a Gardasil setback, impacting investor confidence and market strategy.
Merck & Co., Inc.: Industry Impact and Market Trends Analysis
Merck & Co., Inc. faces securities fraud investigations amid analyst optimism, presenting a complex investment landscape. Key legal, financial, and market insights provided.
Merck (MRK) Under Scrutiny: Securities Fraud Lawsuit Impacts Investors
Merck faces multiple securities fraud lawsuits impacting investor sentiment and stock valuation. Detailed analysis and key insights provided.
Merck Faces Investor Lawsuits Amid Dividend Stock Rotation
Merck (MRK) faces securities fraud lawsuits amidst a dividend stock rotation. Analysis includes allegations, responses, interest rate impacts, and conference participation.
Merck (MRK) News: Keytruda, Lawsuits, and Future Growth Strategies
Merck & Co. navigates Keytruda's success, lawsuits, and strategic growth amid looming price controls and global expansion efforts. A comprehensive market analysis.
Merck (MRK) Under Scrutiny: Class Action Lawsuits and Investor Concerns
Merck (MRK) faces investor lawsuits over Gardasil sales projections, impacting investor confidence and stock. The lead plaintiff deadline is April 14, 2025.
Merck (MRK) Faces Investor Lawsuits: Impact on Stock and Outlook
Merck (MRK) faces investor lawsuits amid promising pipeline developments. Analysis covers legal challenges, oncology portfolio, financial stability, and market outlook.
Merck & Co., Inc.: Intraday Update on Legal and Pipeline News
A comprehensive intraday update for Merck & Co., Inc. on March 5, 2025, covering shareholder lawsuits, patent disputes, and pipeline diversification.
Merck (MRK) Faces Investor Lawsuits: Gardasil Sales Under Scrutiny
Merck (MRK) faces investor lawsuits over Gardasil sales in China amidst Keytruda patent expiration. Dividend yield is attractive, but challenges loom. Stock price: $96.61.
Merck (MRK): Legal Battles, HIV Drug Progress, and Investor Outlook
Analysis of Merck's legal challenges, HIV drug advancements, financial performance, and investor considerations. Stay informed on MRK's market position.
Merck (MRK): Securities Lawsuits, Gardasil Sales, and Investor Risks
Merck (MRK) faces securities lawsuits over Gardasil sales disclosures. Analysis of allegations, financials, and analyst outlook for MRK amidst these challenges.
Merck (MRK) Faces Investor Lawsuits: Analyzing Gardasil Allegations
Merck (MRK) faces investor lawsuits over Gardasil sales allegations. This analysis examines the claims, financial impact, and Merck's defense.
Merck (MRK) Stock Analysis: Navigating Legal Challenges and Growth
Merck (MRK) faces lawsuits amid portfolio expansion. A $2B deal with Jiangsu Hengrui and EU approval for CAPVAXIVE® highlight growth efforts. Dividend appeal key.
Merck (MRK) Stock Analysis: Navigating Lawsuits, Dividends, and Volatility
Analysis of Merck & Co. (MRK) amid lawsuits, tariff risks, and Gardasil uncertainties. Dividend appeal, R&D pipeline, and market sentiment explored.
Merck (MRK) Earnings Preview: Keytruda, Gardasil, and Legal Challenges
Merck (MRK) approaches Q1 2025 earnings, balancing Keytruda strength with Gardasil China headwinds, legal challenges, and industry dynamics.
Merck's Strategic Pivot: Dengue Vaccine Trial and Regulatory Headwinds
Merck's latest strategic moves, including a new dengue vaccine trial and animal health approval, navigate complex regulatory and competitive landscapes.
Merck's Keytruda Approval & Pipeline Progress: An [MRK](/dashboard/companies/MRK) Analysis
Merck's recent FDA approval of Keytruda for head and neck cancer, coupled with advancements in its vaccine and veterinary pipelines, positions the company for continued growth.
Merck & Co. (MRK): Clinical Advances and Regulatory Resilience
Merck & Co. navigates a complex landscape of clinical advancements and regulatory pressures, with its stock reflecting nuanced market sentiment.
Merck's Strategic Evolution: Keytruda's Future & Pipeline Power
Merck secures a pivotal Keytruda FDA approval while accelerating its pipeline to counter patent cliffs and solidify its leadership in oncology and vaccines.
Merck's WINREVAIR™ Triumph: Reshaping PAH Treatment & MRK's Financials
Merck's WINREVAIR™ (sotatercept-csrk) Phase 3 HYPERION study results signal a new era for PAH treatment, bolstering Merck's pipeline and financial outlook.
[MRK](/dashboard/companies/MRK) Strategic Shifts: Winrevair, HIV Pipeline & Financial Health
Unpack Merck's latest developments, from the transformative potential of Winrevair and its HIV pipeline to navigating China sales and robust financial performance.
Merck's Strategic Pivot: Diversifying Beyond Keytruda for Growth
Merck is strategically diversifying beyond Keytruda, leveraging pipeline assets like Winrevair and Enflonsia, and executing targeted M&A to secure post-2028 growth.
Merck & Co. (MRK) Navigates Keytruda Patent Cliff with Strategic Pipeline Expansion and Valuation Insights
Merck confronts Keytruda patent expiry with lifecycle extensions and pipeline growth, balancing revenue risks and valuation discounts amid biosimilar competition.
Merck & Co., Inc. Market Analysis: WINREVAIR Growth and Navigating Keytruda Patent Cliff
Merck's strategic growth through WINREVAIR in PAH market offsets Keytruda patent cliff risks. Analyzing financials, pipeline, and market positioning for investors.
Merck & Co. Strategic Growth and Financial Resilience Amid Keytruda Patent Cliff
Merck pivots with WINREVAIR™ to offset Keytruda patent cliff, highlighting strong financials, pipeline diversification, and sustainable dividends for investors.
Merck & Co., Inc. Strategic $10B Verona Pharma Acquisition and Financial Impact Analysis
Merck's $10B acquisition of Verona Pharma strengthens its COPD portfolio, mitigating Keytruda patent risks and driving future revenue growth.
Merck & Co., Inc. Strategic Diversification and Verona Pharma Acquisition Analysis
Merck's $10B acquisition of Verona Pharma signals a strategic pivot to respiratory medicine, bolstering growth post-Keytruda patent cliff with robust financial backing.
Merck & Co. Strategic Diversification and Financial Resilience Amid Keytruda Patent Cliff | Monexa AI
Merck's $10B Verona Pharma acquisition diversifies revenue beyond Keytruda, strengthening respiratory and HIV pipelines amid patent expiration risks and biosimilar competition.
Merck & Co., Inc. Strategic Growth via $10B Verona Pharma Acquisition and Pipeline Diversification
Merck’s $10B Verona Pharma acquisition bolsters its respiratory and HIV pipeline, offsetting Keytruda patent cliffs amid strong financials and strategic execution.
Merck & Co., Inc. Strategic Pivot and Financial Resilience Analysis | Monexa AI
Merck navigates Keytruda patent expiration with Verona Pharma acquisition, HIV pipeline expansion, and innovative therapies to sustain growth.
Merck & Co., Inc. (MRK) Latest Financial & Strategic Update: Earnings, Expansion, and Market Position
Merck & Co., Inc. shows strong recovery in earnings and cash flow, strategic expansion in animal health, and solid financial metrics supporting growth and dividend sustainability.
Merck & Co., Inc. Q2 2025 Earnings and Strategic Pipeline Growth Analysis | Monexa AI
Merck's Q2 2025 earnings preview highlights Keytruda sales, patent cliff challenges, and pipeline innovations shaping the company's financial outlook.
Merck & Co., Inc. Strategic Restructuring and Pipeline Expansion Amid Keytruda Patent Cliff
Merck launches $3B cost-saving plan to offset Keytruda patent cliff and Gardasil China sales decline, focusing on pipeline growth and strategic reinvestment.
Merck (MRK): KEYTRUDA–Padcev Breakthrough and Financial Impact
Merck’s KEYTRUDA + Padcev perioperative data reshape MIBC care and carry measurable financial and capital-allocation implications for MRK’s oncology franchise and cash flow profile.
Merck & Co. (MRK) — Cash Flow, M&A and Dividend Dynamics
Data-driven update: Merck's 2024 earnings surge, ~$10B Verona deal, $18.1B FCF and the implications for dividend durability and capital allocation.
Merck & Co., Inc. Strategic Response to Keytruda Patent Cliff and Pipeline Diversification
Merck faces the 2028 Keytruda patent cliff with strategic acquisitions and pipeline expansion to sustain growth amid projected revenue declines.
Merck & Co. (MRK): Financial Resilience vs. the Keytruda Cliff
Merck swung to **$17.12B net income in 2024** from ~$0.37B in 2023 while Keytruda drove **~$29.5B** of sales—testing diversification and cash-flow strategy ahead of 2028 exclusivity risk.
Merck's Strategy: Navigating Keytruda Cliff with Pipeline & M&A
Explore Merck's strategic maneuvers, pipeline advancements, and financial health as it navigates the impending Keytruda patent cliff and evolving market dynamics.
Merck & Co. (MRK): $18B FCF Rebound vs. the Keytruda 2028 Test
Merck delivered **$17.12B** net income and **$18.1B** free cash flow in FY2024, restoring balance-sheet flexibility ahead of Keytruda’s 2028 exclusivity risk.
Merck & Co. (MRK): Cash-Flow Comeback vs. a $20B Keytruda Cliff
Merck reported **FY2024 net income $17.12B** and **FCF $18.1B**, a dramatic rebound from 2023 — even as Keytruda’s 2028 patent expiry could create a >$20B revenue gap.
Merck (MRK): Profit Recovery, Keytruda Risks and the Cash‑Fueled Defense of a Blockbuster
Merck swung to **$17.12B net income in FY2024**, generated **$18.1B FCF**, and is deploying cash and pipeline lifecycles to defend Keytruda against biosimilars and new entrants.
Merck & Co.: FY2024 Earnings Bounce, Cash Flow Surge and the R&D Reversion That Changed the Story
Merck posted **$17.12B** net income in FY2024 — a +4593.70% YoY swing — as R&D spend retreated and operating margin expanded to **31.51%**, unlocking cash and strategic optionality.
Merck & Co., Inc. (MRK): FY2024 Turnaround, Enliticide Push, and Cash-Flow Muscle
Merck swung to **$17.12B net income** in FY2024 and generated **$18.1B free cash flow** as Enliticide Phase‑3 readouts reshape the growth outlook.
Merck's Dual Expansion: Verona Pharma and Tulisokibart Pipeline Signal Growth
Pharma giant completes respiratory M&A and expands inflammatory platform, rewarded by 13% surge as investors validate diversification thesis.